Quinoxaline, its derivatives and applications: A State of the Art review

被引：396
作者：
Pereira, Joana A. [1 ]
Pessoa, Ana M. [2 ,3 ]
Cordeiro, M. Natalia D. S. [3 ]
Fernandes, Ruben [1 ,4 ]
Prudencio, Cristina [1 ,4 ,5 ]
Noronha, Joao Paulo [6 ]
Vieira, Monica [1 ,6 ]
机构：
[1] Inst Politecn Porto ESTSP IPP, Escola Super Tecnol Saude, CISA, Ciencias Quim & Biomol, P-4400330 Vila Nova De Gaia, Portugal
[2] REQUIMTE, P-4150180 Oporto, Portugal
[3] Inst Politecn Porto, Escola Super Estudos Ind & Gestao, P-4480876 Vila Do Conde, Portugal
[4] Univ Porto, Fac Med, Ctr Farmacol & Biopatol Quim FCT U38, P-4200319 Oporto, Portugal
[5] ARS Norte, USF Abel Salazar, Oporto, Portugal
[6] Univ Nova Lisboa, FCT, Dept Quim, REQUIMTE CQFB, P-2829516 Caparica, Portugal
来源：
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2015年 / 97卷
关键词：
Quinoxaline; Quinoxaline derivatives; Biological activity; Therapeutic application; Biomedical applications; 1,4-DIOXIDE; INHIBITORS;
D O I：
10.1016/j.ejmech.2014.06.058
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Quinoxaline derivatives are an important class of heterocycle compounds, where N replaces some carbon atoms in the ring of naphthalene. Its molecular formula is C8H6N2, formed by the fusion of two aromatic rings, benzene and pyrazine. It is rare in natural state, but their synthesis is easy to perform. In this review the State of the Art will be presented, which includes a summary of the progress made over the past years in the knowledge of the structure and mechanism of the quinoxaline and quinoxaline derivatives, associated medical and biomedical value as well as industrial value. Modifying quinoxaline structure it is possible to obtain a wide variety of biomedical applications, namely antimicrobial activities and chronic and metabolic diseases treatment. (C) 2014 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：664 / 672
页数：9
相关论文
共 85 条
[51]  
Micklewright R., 2003, PHARMACOL THERAPEUT, V17, P11
[52]  
Montoya M. Elena, 1998, IL FARM, V53, P3
[53]  
Nageswar Y.V.D., 2013, CHEMINFORM, V44
[54]   Antimicrobial resistance [J].
Neely, AN ;
Holder, IA .
BURNS, 1999, 25 (01) :17-24
[55]   PROPOSED ROLES FOR GROWTH-FACTORS IN MEDIATING SMOOTH-MUSCLE PROLIFERATION IN VASCULAR PATHOLOGIES [J].
NEWBY, AC ;
GEORGE, SJ .
CARDIOVASCULAR RESEARCH, 1993, 27 (07) :1173-1183
[56]  
Nollette Kimberly Ann., 2000, Journal of the American Academy of Nurse Practitioners, V12
[57]  
O'Neill Michael J., 2004, CURR DRUG TARGET CNS, V3, P14
[58]  
Obot I.B., 2010, CORROS SCI, V52, P3
[59]   Tuberculosis [J].
Onyebujoh, P ;
Rook, GAW .
NATURE REVIEWS MICROBIOLOGY, 2004, 2 (12) :930-932
[60]   Tuberculosis Clinical Trial Update and the Current Anti-Tuberculosis Drug Portfolio [J].
Palomino, Juan Carlos ;
Martin, Anandi .
CURRENT MEDICINAL CHEMISTRY, 2013, 20 (30) :3785-3796
123456789